Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kolb, C. Hanumegowda, K. Ask, J. Gauldie (Hamilton, Canada). Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 516

Member's Comments

No comment yet.

Related content which might interest you: Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Aerobic exercise reduces lung inflammation and fibrosis mediated by serotoninergic/Akt signaling in a model of pulmonary fibrosis Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Regulation of WISP1 by profibrotic cytokines in pulmonary fibrosis Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy Source: International Congress 2016 – IPF pathogenesis Year: 2016 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Severe lung inflammation is a feature of IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Hypoxic challenge testing in idiopathic pulmonary fibrosis Source: International Congress 2016 – Orphan diseases I Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Platelet-endothelial adhesion in IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Role of Wnt-1, Wnt-3 and MMP-7 in fibrotic response in extrinsic allergic alveolitis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015